ACT 277--DAPSONE VS ATOVAQUONE FOR PCP PROPHYLAXIS

ACT 277——氨苯砜与阿托伐醌用于 PCP 预防

• 批准号: 6274486
• 负责人: ROB R MACGREGOR
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-15 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274486
• 关键词: AIDS; HIV infections; Pneumocystis pneumonia; atovaquone; chemoprevention; clinical research; clinical trials; dapsone; disease /disorder prevention /control; drug screening /evaluation; human subject; human therapy evaluation; microorganism disease chemotherapy; opportunistic infections; outcomes research; toxoplasmosis

The purpose of this study is to compare the safety and efficacy of dapsone and atovaquone in the prevention of PCP in HIV infected patients who are at high risk for PCP and who are intolerant of TMP/SMX. This study will also compare the incidence of toxoplasmosis in the two treatment groups.

本研究的目的是比较 氨苯砜和阿托伐醌预防HIV感染者发生PCP 五氯苯酚高危人群和TMP/SMX不耐受人群。 这 研究还将比较两个国家弓形虫病的发病率。 治疗组。